Brenda Gati Mirembe
Biographic Data
| ID | 7728180 |
|---|---|
| NAME | Brenda Gati Mirembe |
| GIVEN NAMES | Brenda Gati |
| FAMILY NAME | Mirembe |
| SIGNATURE | MIREMBE B G |
| AFFILIATIONS | MUJHU Research Collaboration |
| ORCID | 0000-0001-9074-6751 |
| VERIFIED | Yes |
| TOTAL WORKS | 7 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 7 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Strengthening implementation science research to improve adolescent and young adult HIV-prevention and care in Sub-Saharan Africa
Not Applicable
Acceptability of the dapivirine vaginal ring for HIV-1 prevention among women reporting engagement in transactional sex
We assessed if acceptability of the dapivirine vaginal ring for HIV prevention differed among the subgroup of women who reported engaging in transactional sex prior to enrollment in MTN-020/ASPIRE (phase III trial in Malawi, South Africa, Uganda, and Zimbabwe, 2012-2015; n = 2629). Transactional sex was defined as receipt of money, goods, gifts, drugs, or shelter in exchange for sex in the past year. Dimensions of acceptability included: ease of …
Efficacy of the Dapivirine Vaginal Ring Accounting for Imperfect Adherence
Feasibility and acceptability of peer-delivered HIV self-testing and PrEP for young women in Kampala, Uganda
Peer delivery of HIVST and oral PrEP was feasible and acceptable to this sample of young women with suboptimal PrEP adherence in Uganda. Future larger controlled studies should evaluate its effectiveness among African AGWY
Correlates of Dapivirine Vaginal Ring Acceptance among Women Participating in an Open Label Extension Trial
Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention
Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial
We evaluated the acceptability of the 25 mg dapivirine vaginal ring (DVR) as an HIV prevention intervention and its influence on DVR adherence in the MTN-020/ASPIRE phase III trial. Acceptability measures were captured using ACASI at month 3 and end of product use (median 24 months, IQR 15-30). Monthly returned rings were classified as nonadherent if dapivirine release rate was ≤ 0.9 mg/month. Associations between acceptability measures and nonad…
No prominent works on this page.
Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention
Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial
We evaluated the acceptability of the 25 mg dapivirine vaginal ring (DVR) as an HIV prevention intervention and its influence on DVR adherence in the MTN-020/ASPIRE phase III trial. Acceptability measures were captured using ACASI at month 3 and end of product use (median 24 months, IQR 15-30). Monthly returned rings were classified as nonadherent if dapivirine release rate was ≤ 0.9 mg/month. Associations between acceptability measures and nonad…
Correlates of Dapivirine Vaginal Ring Acceptance among Women Participating in an Open Label Extension Trial
Feasibility and acceptability of peer-delivered HIV self-testing and PrEP for young women in Kampala, Uganda
Peer delivery of HIVST and oral PrEP was feasible and acceptable to this sample of young women with suboptimal PrEP adherence in Uganda. Future larger controlled studies should evaluate its effectiveness among African AGWY
Acceptability of the dapivirine vaginal ring for HIV-1 prevention among women reporting engagement in transactional sex
We assessed if acceptability of the dapivirine vaginal ring for HIV prevention differed among the subgroup of women who reported engaging in transactional sex prior to enrollment in MTN-020/ASPIRE (phase III trial in Malawi, South Africa, Uganda, and Zimbabwe, 2012-2015; n = 2629). Transactional sex was defined as receipt of money, goods, gifts, drugs, or shelter in exchange for sex in the past year. Dimensions of acceptability included: ease of …
Efficacy of the Dapivirine Vaginal Ring Accounting for Imperfect Adherence
Strengthening implementation science research to improve adolescent and young adult HIV-prevention and care in Sub-Saharan Africa
Not Applicable
Adolescent Sexual and Reproductive Health (6 works) · Environmental health (6 works) · HIV/AIDS Research and Interventions (6 works) · Medicine (6 works) · Family planning (5 works) · HIV, Drug Use, Sexual Risk (5 works) · Population (5 works) · Vaginal ring (5 works) · Family medicine (4 works) · Gynecology (4 works)